Newron Pharmaceuticals SpA

At Newron, we’re heading into 2025 with strong momentum, advancing #evenamide, our lead investigational therapy for treatment-resistant #schizophrenia. With key clinical milestones ahead and expanding global partnerships, we’re dedicated to bringing new treatment possibilities to patients who need it most. Want to know what’s next for evenamide and how we’re shaping the future of schizophrenia care? Swipe through to explore the latest updates and what’s coming soon! #Newron #Outlook2025 #StayTuned

Where biotech meets investment – BIO CEO & Investor Conference 2025! On February 10-11, New York City will become the hub for the #biotech industry’s brightest minds, top investors, and forward-thinking executives. #BIOCEO2025 is more than just a conference – it’s a launchpad for strategic partnerships, breakthrough innovations, and the next wave of #healthcare advancements. Our CEO, Stefan Weber, will be attending to connect with industry leaders and investors to explore new opportunities. With #evenamide, our pioneering investigational add-on therapy for chronic and treatment-resistant #schizophrenia, advancing through critical clinical milestones, we look forward to engaging in discussions that will help shape the future of CNS treatments. Will you be there? Let’s connect and drive the next wave of #innovation together! #Newron #Networking #PatientCare 

Schizophrenia remains one of the most mysterious and challenging conditions in medicine, yet progress is being made. In a recent article by Martin Lindner for WELT am Sonntag, Newron Pharmaceuticals is recognized as one of the innovators leading the way in advancing groundbreaking treatments. Our investigational therapy, #evenamide, has been acknowledged for its potential to become a game-changing add-on treatment for patients who don’t respond adequately to existing antipsychotic medications. This recognition highlights our ongoing commitment to improving the lives of people living with #schizophrenia. Curious about the future of schizophrenia care? Be sure to check out the printed article in the latest issue of Welt am Sonntag, where our CEO, Stefan Weber, shares his insights. #Newron #SchizophreniaAwareness #Innovation #MentalHealth #WeltAmSonntag 

We are proud to share that our CEO, Stefan Weber, has been featured in a recent Scrip article: "Scrip Asks…What Does 2025 Hold For Biopharma? Part 2: Funding, M&A And Partnering" by Eleanor Malone, Editor in Chief of Scrip at Citeline. 📰 The article dives into expert perspectives on the trends shaping the #biopharma landscape in 2025, with a focus on critical topics such as funding challenges, strategic M&A, public markets, venture capital, and the role of partnerships in driving #innovation. 💬 Stefan shared his insights on these key developments, particularly highlighting what he sees as the biggest opportunities and challenges for biopharma partnerships. 💡 Curious to learn more about his thoughts and the broader industry outlook? Read the full article here (€): https://lnkd.in/eR65KVNw #Newron #Collaboration #MacroEconomics

We are thrilled to announce that our CEO, Stefan Weber, will join industry leaders at the 43rd Annual J.P. Morgan Healthcare Conference in #SanFrancisco from January 13-16, 2025! #JPM2025, the premier global #healthcare event, provides an invaluable platform for #Newron to share updates on our groundbreaking work, including #evenamide, our investigational add-on therapy for chronic and treatment-resistant #schizophrenia. At Newron, we remain deeply committed to advancing therapies for central nervous system (CNS) disorders and rare diseases. Will you be attending? Let’s connect to explore how we can shape the future of CNS therapies together. 🤝 #Networking #PatientCare

🌟 New Partnership Announcement We are excited to share that we have entered into a license agreement with Myung In Pharm to develop, manufacture, and commercialize our lead compound, #evenamide, in #South #Korea. This collaboration combines #Newron's innovative approach with Myung In Pharm's clinical expertise and robust infrastructure in the CNS field. 💡 What this partnership brings: ▶️ Global Impact: Myung In Pharm will contribute 10% of patients to our pivotal Phase III trial (expected to begin in H1 2025) and share global development costs ▶️ Regional Expertise: Myung In Pharm will lead regulatory, marketing, and commercialization efforts in South Korea, ensuring evenamide reaches patients effectively ▶️ Shared Success: Newron will receive an upfront payment, development and regulatory milestone payments, and royalties on net sales This agreement builds on the momentum of recent milestones as we unlock new opportunities for evenamide in other Asian territories. We’re grateful for the trust and collaboration of our partners and look forward to jointly advance healthcare and deliver transformative therapies to patients. #Innovation #Neuroscience #Partnerships

We are excited to announce our participation in the Baader Helvea Swiss Equities Conference in Bad Ragaz this Friday, January 10, 2025! Our CEO, Stefan Weber, will present at 09:50 CET, providing updates on Newron’s innovative programs and strategic priorities, highlighting the progress of #evenamide, our investigational add-on therapy for chronic and treatment-resistant #schizophrenia, and its potential to address significant unmet needs in CNS disorders. In addition to the presentation, we look forward to engaging in #investor meetings. We are honored to join this prestigious conference organized by Baader Bank AG. Stay tuned for updates, and we look forward to connecting at the event! #Biotech #InvestorRelations #Networking #Healthcareinnovation

🎉 2024 has been a remarkable year for Newron Pharmaceuticals – filled with progress, milestones, and gratitude. We celebrated major achievements such as the partnering agreement and the excellent clinical results for #evenamide, all made possible by the dedication of our team, the support of our partners, and the trust of our investors. As we reflect on these #milestones, we are looking ahead to 2025 with enthusiasm and ambition. Stay tuned for updates as we continue to push boundaries in (treatment-resistant) #schizophrenia. From all of us at #Newron, we wish you a successful start to the New Year! 🌟 Thank you for being part of our journey. #YearInReview #SeasonsGreetings

We are excited to share that our progress with #evenamide, our innovative investigational treatment for (treatment-resistant) #schizophrenia, has been featured in a recent article by James Waldron on Fierce Biotech. 📰 The article highlights the license agreement worth €117 million plus tiered royalties of up to double-digit percentage of net sales for evenamide, with EA Pharma, a subsidiary of Eisai Co., Ltd., granting them rights in #Japan and other Asian territories.   💡Curious to learn more about this agreement and what it means for Newron’s global strategy? Check out the full article here: https://lnkd.in/dNQ9eJEZ #Newron #Innovation #Neuroscience #Partnerships

📢 Major Milestone Alert! We are thrilled to announce that we have entered into a license agreement with EA Pharma, a subsidiary of Eisai Co., Ltd., for our lead compound, #evenamide. This partnership marks a significant #milestone for our company and the future of treatment for patients with (treatment-resistant) #schizophrenia. 🌟 Key Highlights of the Agreement: - EA Pharma will develop, manufacture and commercialize our innovative modulator of excessive glutamate, evenamide, in Japan and other designated Asian territories - Newron will receive up to a maximum total of €117m, structured as: >An upfront payment of €44m >Financial contributions for our upcoming Phase III study in H1 2025 >Milestone payments tied to regulatory and commercialization achievements In addition, Newron will receive tiered royalties of up to double-digit percentage of net sales for evenamide. 🌍 Together, with EA Pharma, we are working to bring evenamide to patients worldwide and explore further development opportunities in other territories. 👉 Stay tuned for updates on this exciting journey! #Newron #Innovation #Neuroscience #Partnerships